NasdaqCM:ELTXBiotechs
Elicio Therapeutics (ELTX) Is Down 69.9% After Phase 2 ELI-002 Miss in Pancreatic Cancer Trial
Elicio Therapeutics recently reported that its Phase 2 AMPLIFY-7P trial of ELI-002 7P in adjuvant pancreatic cancer did not meet the pre-specified primary disease-free survival endpoint in the intent-to-treat population, although the company highlighted imbalances in high-risk R1 resections between treatment and observation arms.
Post-hoc analyses showed improved disease-free survival and strong mutant KRAS-specific immune responses in R0 resected patients, prompting Elicio to redesign a...

